Is immunohistochemistry always required to diagnose lung cancer?

Giulio Rossi, Marcello Tiseo, Alberto Cavazza, Thomas V. Colby

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Non-small cell lung cancer is possibly the solid tumor with more potential drugable molecular targets, but the smallest tumor specimens. An optimization of tumor tissue handling is then mandatory. In this landscape, the precise definition of non-small cell lung cancer histologic type had a renewal role in selecting different therapeutic strategies, also leading to a large use of immunohistochemistry even in malignancies showing an overt morphologic differentiation. We suggest here 4 different clinicopathologic scenarios with some helpful rules aimed at preventing unnecessary and expensive immunostains, then underlining the ageless value of morphology and preserving tumor tissues for molecular investigations.

Original languageEnglish (US)
Pages (from-to)327-333
Number of pages7
JournalAdvances in Anatomic Pathology
Volume20
Issue number5
DOIs
StatePublished - Sep 2013

Fingerprint

Lung Neoplasms
Immunohistochemistry
Neoplasms
Non-Small Cell Lung Carcinoma
Therapeutics

Keywords

  • diagnosis
  • imaging
  • immunohistochemistry
  • Lung cancer
  • metastasis

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Anatomy

Cite this

Is immunohistochemistry always required to diagnose lung cancer? / Rossi, Giulio; Tiseo, Marcello; Cavazza, Alberto; Colby, Thomas V.

In: Advances in Anatomic Pathology, Vol. 20, No. 5, 09.2013, p. 327-333.

Research output: Contribution to journalArticle

Rossi, Giulio ; Tiseo, Marcello ; Cavazza, Alberto ; Colby, Thomas V. / Is immunohistochemistry always required to diagnose lung cancer?. In: Advances in Anatomic Pathology. 2013 ; Vol. 20, No. 5. pp. 327-333.
@article{0644c42e65294084aa791dc84ff74f7a,
title = "Is immunohistochemistry always required to diagnose lung cancer?",
abstract = "Non-small cell lung cancer is possibly the solid tumor with more potential drugable molecular targets, but the smallest tumor specimens. An optimization of tumor tissue handling is then mandatory. In this landscape, the precise definition of non-small cell lung cancer histologic type had a renewal role in selecting different therapeutic strategies, also leading to a large use of immunohistochemistry even in malignancies showing an overt morphologic differentiation. We suggest here 4 different clinicopathologic scenarios with some helpful rules aimed at preventing unnecessary and expensive immunostains, then underlining the ageless value of morphology and preserving tumor tissues for molecular investigations.",
keywords = "diagnosis, imaging, immunohistochemistry, Lung cancer, metastasis",
author = "Giulio Rossi and Marcello Tiseo and Alberto Cavazza and Colby, {Thomas V.}",
year = "2013",
month = "9",
doi = "10.1097/PAP.0b013e3182a28a24",
language = "English (US)",
volume = "20",
pages = "327--333",
journal = "Advances in Anatomic Pathology",
issn = "1072-4109",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Is immunohistochemistry always required to diagnose lung cancer?

AU - Rossi, Giulio

AU - Tiseo, Marcello

AU - Cavazza, Alberto

AU - Colby, Thomas V.

PY - 2013/9

Y1 - 2013/9

N2 - Non-small cell lung cancer is possibly the solid tumor with more potential drugable molecular targets, but the smallest tumor specimens. An optimization of tumor tissue handling is then mandatory. In this landscape, the precise definition of non-small cell lung cancer histologic type had a renewal role in selecting different therapeutic strategies, also leading to a large use of immunohistochemistry even in malignancies showing an overt morphologic differentiation. We suggest here 4 different clinicopathologic scenarios with some helpful rules aimed at preventing unnecessary and expensive immunostains, then underlining the ageless value of morphology and preserving tumor tissues for molecular investigations.

AB - Non-small cell lung cancer is possibly the solid tumor with more potential drugable molecular targets, but the smallest tumor specimens. An optimization of tumor tissue handling is then mandatory. In this landscape, the precise definition of non-small cell lung cancer histologic type had a renewal role in selecting different therapeutic strategies, also leading to a large use of immunohistochemistry even in malignancies showing an overt morphologic differentiation. We suggest here 4 different clinicopathologic scenarios with some helpful rules aimed at preventing unnecessary and expensive immunostains, then underlining the ageless value of morphology and preserving tumor tissues for molecular investigations.

KW - diagnosis

KW - imaging

KW - immunohistochemistry

KW - Lung cancer

KW - metastasis

UR - http://www.scopus.com/inward/record.url?scp=84883414342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883414342&partnerID=8YFLogxK

U2 - 10.1097/PAP.0b013e3182a28a24

DO - 10.1097/PAP.0b013e3182a28a24

M3 - Article

C2 - 23939149

AN - SCOPUS:84883414342

VL - 20

SP - 327

EP - 333

JO - Advances in Anatomic Pathology

JF - Advances in Anatomic Pathology

SN - 1072-4109

IS - 5

ER -